Concepts (236)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Polyendocrinopathies, Autoimmune | 4 | 2021 | 129 | 1.94 | Why? |
| CARD Signaling Adaptor Proteins | 2 | 2018 | 70 | 1.44 | Why? |
| Candidiasis | 4 | 2019 | 334 | 1.25 | Why? |
| Aspergillosis | 3 | 2018 | 264 | 1.21 | Why? |
| Mycoses | 3 | 2018 | 589 | 1.16 | Why? |
| Candida albicans | 5 | 2019 | 217 | 1.15 | Why? |
| Autoantibodies | 6 | 2021 | 2094 | 1.15 | Why? |
| Fungi | 4 | 2018 | 471 | 1.08 | Why? |
| Candidiasis, Cutaneous | 1 | 2021 | 8 | 0.95 | Why? |
| Interferon Type I | 5 | 2021 | 2789 | 0.89 | Why? |
| Candidiasis, Oral | 2 | 2018 | 58 | 0.85 | Why? |
| Transcription Factors | 3 | 2021 | 784 | 0.84 | Why? |
| STAT3 Transcription Factor | 3 | 2018 | 268 | 0.82 | Why? |
| Invasive Fungal Infections | 3 | 2018 | 274 | 0.82 | Why? |
| CX3C Chemokine Receptor 1 | 1 | 2018 | 21 | 0.74 | Why? |
| Gliotoxin | 1 | 2017 | 3 | 0.73 | Why? |
| Immunologic Surveillance | 1 | 2018 | 69 | 0.72 | Why? |
| Eosinophilic Esophagitis | 1 | 2018 | 35 | 0.72 | Why? |
| Candida glabrata | 1 | 2018 | 50 | 0.70 | Why? |
| Neutropenia | 2 | 2018 | 388 | 0.68 | Why? |
| Immunologic Deficiency Syndromes | 2 | 2018 | 368 | 0.66 | Why? |
| Candidiasis, Invasive | 1 | 2017 | 107 | 0.63 | Why? |
| Meningoencephalitis | 1 | 2018 | 208 | 0.59 | Why? |
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2018 | 290 | 0.59 | Why? |
| Tetrazoles | 1 | 2018 | 262 | 0.57 | Why? |
| Host-Pathogen Interactions | 4 | 2021 | 11041 | 0.56 | Why? |
| Antifungal Agents | 4 | 2018 | 1828 | 0.55 | Why? |
| Aspergillus | 1 | 2017 | 347 | 0.55 | Why? |
| Chemoprevention | 1 | 2018 | 585 | 0.53 | Why? |
| Pyrimidines | 3 | 2018 | 1557 | 0.50 | Why? |
| Moths | 1 | 2011 | 24 | 0.48 | Why? |
| Mice, Knockout | 4 | 2018 | 1815 | 0.48 | Why? |
| Cell Survival | 1 | 2018 | 1581 | 0.47 | Why? |
| Drosophila | 1 | 2011 | 55 | 0.47 | Why? |
| Lymphoma | 1 | 2017 | 522 | 0.46 | Why? |
| Pyridines | 1 | 2018 | 680 | 0.45 | Why? |
| Rhinitis, Allergic | 1 | 2018 | 704 | 0.43 | Why? |
| Pyrazoles | 3 | 2018 | 1791 | 0.42 | Why? |
| Brain Neoplasms | 1 | 2017 | 669 | 0.41 | Why? |
| Hematologic Neoplasms | 2 | 2018 | 2105 | 0.36 | Why? |
| Enzyme Inhibitors | 2 | 2021 | 1881 | 0.34 | Why? |
| Monocytes | 2 | 2020 | 2978 | 0.31 | Why? |
| Mouth Mucosa | 2 | 2018 | 323 | 0.28 | Why? |
| T-Lymphocytes | 1 | 2021 | 6670 | 0.26 | Why? |
| Autoimmunity | 2 | 2021 | 841 | 0.25 | Why? |
| Signal Transduction | 6 | 2018 | 7207 | 0.24 | Why? |
| Clonal Selection, Antigen-Mediated | 1 | 2021 | 45 | 0.23 | Why? |
| Animals | 15 | 2021 | 78931 | 0.23 | Why? |
| Disease Susceptibility | 3 | 2021 | 4002 | 0.23 | Why? |
| Immune Tolerance | 3 | 2021 | 608 | 0.22 | Why? |
| Pneumonia | 1 | 2021 | 5652 | 0.22 | Why? |
| Adenine | 3 | 2018 | 463 | 0.21 | Why? |
| Laminin | 1 | 2019 | 23 | 0.20 | Why? |
| Symbiosis | 1 | 2019 | 38 | 0.20 | Why? |
| Job Syndrome | 1 | 2018 | 15 | 0.19 | Why? |
| Ursidae | 1 | 2018 | 9 | 0.19 | Why? |
| Janus Kinase 1 | 1 | 2021 | 254 | 0.19 | Why? |
| Janus Kinase 2 | 1 | 2021 | 218 | 0.19 | Why? |
| Disease Models, Animal | 3 | 2017 | 10998 | 0.19 | Why? |
| Haploinsufficiency | 1 | 2018 | 28 | 0.19 | Why? |
| Fungal Vaccines | 1 | 2017 | 1 | 0.19 | Why? |
| Culture Media, Serum-Free | 1 | 2018 | 29 | 0.18 | Why? |
| Receptor, EphA2 | 1 | 2017 | 17 | 0.18 | Why? |
| Chemokine CX3CL1 | 1 | 2018 | 26 | 0.18 | Why? |
| MAP Kinase Signaling System | 1 | 2021 | 360 | 0.18 | Why? |
| CD79 Antigens | 1 | 2017 | 5 | 0.18 | Why? |
| Proteoglycans | 1 | 2019 | 130 | 0.18 | Why? |
| Staphylococcal Protein A | 1 | 2017 | 32 | 0.18 | Why? |
| Gain of Function Mutation | 1 | 2017 | 54 | 0.17 | Why? |
| Neovascularization, Physiologic | 1 | 2019 | 160 | 0.17 | Why? |
| Microbiota | 2 | 2018 | 1240 | 0.17 | Why? |
| Magnetic Fields | 1 | 2017 | 26 | 0.17 | Why? |
| Granulomatous Disease, Chronic | 1 | 2017 | 60 | 0.17 | Why? |
| Benzamides | 1 | 2020 | 421 | 0.17 | Why? |
| Collagen | 1 | 2019 | 222 | 0.17 | Why? |
| Debridement | 1 | 2018 | 172 | 0.17 | Why? |
| Homozygote | 1 | 2018 | 230 | 0.16 | Why? |
| Myeloid Differentiation Factor 88 | 1 | 2017 | 109 | 0.16 | Why? |
| Fluconazole | 1 | 2018 | 145 | 0.16 | Why? |
| Receptors, Pattern Recognition | 1 | 2017 | 128 | 0.16 | Why? |
| Thymus Gland | 1 | 2017 | 126 | 0.16 | Why? |
| Piperidines | 3 | 2018 | 795 | 0.16 | Why? |
| Bronchiectasis | 1 | 2021 | 312 | 0.16 | Why? |
| Mammals | 1 | 2019 | 315 | 0.16 | Why? |
| Gene Knockout Techniques | 1 | 2017 | 347 | 0.16 | Why? |
| Drug Resistance, Fungal | 1 | 2018 | 191 | 0.15 | Why? |
| Protein-Tyrosine Kinases | 1 | 2017 | 158 | 0.15 | Why? |
| Mice | 5 | 2018 | 21357 | 0.15 | Why? |
| Transplantation, Homologous | 1 | 2018 | 757 | 0.15 | Why? |
| beta-Glucans | 1 | 2017 | 176 | 0.15 | Why? |
| Mutation | 5 | 2019 | 12376 | 0.15 | Why? |
| STAT1 Transcription Factor | 1 | 2017 | 313 | 0.15 | Why? |
| Ubiquitin | 1 | 2017 | 243 | 0.15 | Why? |
| Antigen-Antibody Complex | 1 | 2017 | 408 | 0.15 | Why? |
| Receptors, Antigen, B-Cell | 1 | 2017 | 424 | 0.14 | Why? |
| Complement Activation | 1 | 2021 | 949 | 0.14 | Why? |
| Triazoles | 1 | 2018 | 440 | 0.14 | Why? |
| Immunotherapy | 2 | 2018 | 2421 | 0.13 | Why? |
| Sjogren's Syndrome | 1 | 2017 | 284 | 0.13 | Why? |
| Adaptor Proteins, Signal Transducing | 1 | 2018 | 502 | 0.13 | Why? |
| Neovascularization, Pathologic | 1 | 2017 | 305 | 0.13 | Why? |
| Cell Culture Techniques | 1 | 2018 | 704 | 0.13 | Why? |
| Mice, Inbred C57BL | 3 | 2019 | 5542 | 0.13 | Why? |
| Gene Expression | 2 | 2021 | 3332 | 0.12 | Why? |
| Dysbiosis | 1 | 2018 | 685 | 0.12 | Why? |
| Pulmonary Aspergillosis | 1 | 2017 | 408 | 0.12 | Why? |
| Dendritic Cells | 1 | 2021 | 1330 | 0.12 | Why? |
| Healthy Volunteers | 1 | 2018 | 1444 | 0.12 | Why? |
| Humans | 30 | 2021 | 930598 | 0.11 | Why? |
| Steroids | 1 | 2017 | 904 | 0.11 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 2017 | 533 | 0.11 | Why? |
| Epithelial Cells | 2 | 2021 | 3508 | 0.11 | Why? |
| Killer Cells, Natural | 1 | 2021 | 2093 | 0.11 | Why? |
| Immunity, Innate | 2 | 2018 | 6570 | 0.10 | Why? |
| Membrane Glycoproteins | 1 | 2019 | 2273 | 0.10 | Why? |
| Pyrazines | 1 | 2020 | 1783 | 0.09 | Why? |
| Microbial Sensitivity Tests | 1 | 2018 | 2886 | 0.09 | Why? |
| Gene Expression Regulation | 2 | 2018 | 4020 | 0.09 | Why? |
| Fatal Outcome | 1 | 2018 | 3438 | 0.09 | Why? |
| Bacterial Proteins | 1 | 2017 | 1318 | 0.09 | Why? |
| Endothelial Cells | 1 | 2019 | 2048 | 0.09 | Why? |
| Immune System | 1 | 2017 | 1479 | 0.09 | Why? |
| Protein Kinase Inhibitors | 1 | 2018 | 1585 | 0.09 | Why? |
| Apoptosis | 1 | 2018 | 2335 | 0.08 | Why? |
| Cells, Cultured | 1 | 2018 | 5835 | 0.08 | Why? |
| Adaptive Immunity | 1 | 2017 | 2585 | 0.08 | Why? |
| Autoantigens | 2 | 2019 | 388 | 0.07 | Why? |
| Hematopoietic Stem Cell Transplantation | 1 | 2018 | 2426 | 0.07 | Why? |
| B-Lymphocytes | 1 | 2019 | 4418 | 0.07 | Why? |
| Phosphorylation | 2 | 2017 | 1060 | 0.07 | Why? |
| Cytokines | 3 | 2021 | 15010 | 0.06 | Why? |
| Point-of-Care Systems | 1 | 2017 | 2955 | 0.06 | Why? |
| Genetic Predisposition to Disease | 1 | 2018 | 4027 | 0.06 | Why? |
| Drug Therapy, Combination | 1 | 2017 | 7268 | 0.06 | Why? |
| Cell Line, Tumor | 2 | 2021 | 3608 | 0.06 | Why? |
| Male | 12 | 2021 | 367725 | 0.06 | Why? |
| Complement Factor B | 1 | 2021 | 36 | 0.06 | Why? |
| Biomarkers | 3 | 2021 | 23361 | 0.06 | Why? |
| Adult | 7 | 2021 | 244371 | 0.06 | Why? |
| Magnetic Resonance Imaging | 1 | 2018 | 6551 | 0.06 | Why? |
| Female | 11 | 2021 | 380317 | 0.05 | Why? |
| Complement C3a | 1 | 2021 | 73 | 0.05 | Why? |
| Immunocompromised Host | 1 | 2017 | 5150 | 0.05 | Why? |
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2021 | 92 | 0.05 | Why? |
| Chemokine CXCL9 | 1 | 2021 | 154 | 0.05 | Why? |
| Neoplasms | 2 | 2021 | 17251 | 0.05 | Why? |
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2021 | 120 | 0.05 | Why? |
| Disease Management | 1 | 2018 | 6841 | 0.05 | Why? |
| Calgranulin B | 1 | 2021 | 144 | 0.05 | Why? |
| Interleukin-15 | 1 | 2021 | 169 | 0.05 | Why? |
| Middle Aged | 9 | 2021 | 270681 | 0.05 | Why? |
| Prospective Studies | 3 | 2021 | 43301 | 0.05 | Why? |
| Virus Replication | 1 | 2021 | 14331 | 0.05 | Why? |
| Microtomy | 1 | 2019 | 12 | 0.05 | Why? |
| Lipocalin-2 | 1 | 2021 | 156 | 0.05 | Why? |
| Matrix Metalloproteinase 9 | 1 | 2021 | 211 | 0.05 | Why? |
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2021 | 229 | 0.05 | Why? |
| Streptococcus oralis | 1 | 2018 | 4 | 0.05 | Why? |
| Streptococcus mutans | 1 | 2018 | 15 | 0.05 | Why? |
| Immunosuppressive Agents | 1 | 2018 | 6331 | 0.05 | Why? |
| Interleukin-2 | 1 | 2021 | 443 | 0.05 | Why? |
| Paraffin Embedding | 1 | 2019 | 105 | 0.05 | Why? |
| Lactoferrin | 1 | 2021 | 208 | 0.05 | Why? |
| Risk Factors | 2 | 2018 | 71621 | 0.05 | Why? |
| Chemokine CCL2 | 1 | 2021 | 389 | 0.05 | Why? |
| SUMO-1 Protein | 1 | 2017 | 13 | 0.05 | Why? |
| Travel | 1 | 2017 | 7220 | 0.05 | Why? |
| Sumoylation | 1 | 2017 | 21 | 0.05 | Why? |
| CD3 Complex | 1 | 2019 | 237 | 0.04 | Why? |
| Candidiasis, Chronic Mucocutaneous | 1 | 2017 | 17 | 0.04 | Why? |
| Aged, 80 and over | 5 | 2021 | 88759 | 0.04 | Why? |
| Microscopy, Fluorescence | 1 | 2019 | 335 | 0.04 | Why? |
| Staining and Labeling | 1 | 2019 | 169 | 0.04 | Why? |
| COS Cells | 1 | 2017 | 157 | 0.04 | Why? |
| Gastritis | 1 | 2017 | 66 | 0.04 | Why? |
| Case-Control Studies | 3 | 2021 | 17671 | 0.04 | Why? |
| Antibodies, Neutralizing | 2 | 2021 | 25288 | 0.04 | Why? |
| Cell Separation | 1 | 2019 | 270 | 0.04 | Why? |
| Protein Array Analysis | 1 | 2019 | 387 | 0.04 | Why? |
| Italy | 1 | 2021 | 38444 | 0.04 | Why? |
| Transcriptional Activation | 1 | 2017 | 196 | 0.04 | Why? |
| Dental Caries | 1 | 2018 | 163 | 0.04 | Why? |
| Severity of Illness Index | 2 | 2021 | 48226 | 0.04 | Why? |
| ErbB Receptors | 1 | 2017 | 320 | 0.04 | Why? |
| Young Adult | 3 | 2021 | 93724 | 0.04 | Why? |
| RNA, Ribosomal, 16S | 1 | 2018 | 793 | 0.04 | Why? |
| Child | 2 | 2021 | 70012 | 0.03 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.03 | Why? |
| Endocytosis | 1 | 2017 | 451 | 0.03 | Why? |
| Transfection | 1 | 2017 | 864 | 0.03 | Why? |
| Interleukin-10 | 1 | 2021 | 1409 | 0.03 | Why? |
| Aged | 6 | 2021 | 215776 | 0.03 | Why? |
| Interleukin-17 | 1 | 2018 | 602 | 0.03 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.03 | Why? |
| Adolescent | 2 | 2021 | 86841 | 0.03 | Why? |
| NF-kappa B | 1 | 2021 | 1301 | 0.03 | Why? |
| Th17 Cells | 1 | 2018 | 657 | 0.03 | Why? |
| T-Lymphocytes, Regulatory | 1 | 2019 | 698 | 0.03 | Why? |
| Interleukin-6 | 2 | 2021 | 7522 | 0.03 | Why? |
| Esophageal Neoplasms | 1 | 2017 | 357 | 0.03 | Why? |
| Lung | 1 | 2021 | 31049 | 0.03 | Why? |
| Ferritins | 1 | 2021 | 2055 | 0.03 | Why? |
| Cell Line | 2 | 2017 | 12040 | 0.03 | Why? |
| Transcription, Genetic | 1 | 2017 | 1326 | 0.03 | Why? |
| Interferon-gamma | 1 | 2021 | 2711 | 0.03 | Why? |
| Flow Cytometry | 1 | 2019 | 2393 | 0.03 | Why? |
| Multivariate Analysis | 1 | 2021 | 5440 | 0.02 | Why? |
| Gene Expression Profiling | 1 | 2021 | 3788 | 0.02 | Why? |
| Lymphocyte Activation | 1 | 2019 | 2742 | 0.02 | Why? |
| Drug Combinations | 1 | 2019 | 3852 | 0.02 | Why? |
| Proteomics | 1 | 2019 | 2481 | 0.02 | Why? |
| Transcriptome | 1 | 2021 | 3466 | 0.02 | Why? |
| Critical Illness | 2 | 2020 | 17281 | 0.02 | Why? |
| Phenotype | 1 | 2017 | 4037 | 0.02 | Why? |
| Inflammation | 2 | 2020 | 13255 | 0.02 | Why? |
| Inflammation Mediators | 1 | 2017 | 2654 | 0.02 | Why? |
| Azithromycin | 1 | 2021 | 3943 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2021 | 9893 | 0.02 | Why? |
| Immunologic Factors | 1 | 2021 | 4206 | 0.02 | Why? |
| Adrenal Cortex Hormones | 1 | 2021 | 6537 | 0.02 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.01 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2020 | 17020 | 0.01 | Why? |
| Asymptomatic Infections | 1 | 2020 | 7218 | 0.01 | Why? |
| Inflammatory Bowel Diseases | 1 | 2017 | 3209 | 0.01 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.01 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 9335 | 0.01 | Why? |
| Anti-Bacterial Agents | 1 | 2021 | 10083 | 0.01 | Why? |
| Prognosis | 1 | 2021 | 32490 | 0.01 | Why? |
| Hydroxychloroquine | 1 | 2021 | 12447 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2020 | 21571 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.01 | Why? |
| Child, Preschool | 1 | 2019 | 36283 | 0.01 | Why? |
| Treatment Outcome | 1 | 2020 | 51732 | 0.01 | Why? |
| Antiviral Agents | 1 | 2021 | 41703 | 0.01 | Why? |
| Pandemics | 2 | 2020 | 389249 | 0.00 | Why? |